Pegloticase injecatble

Pegloticase injecatble

Form: Injectable (IV solution)

Strength: 8 mg/1.2 mL vial

Reference Brands: Krystexxa (US)

Category: Arthritis

Pegloticase injectable is approved in the US for the treatment of severe, refractory gout unresponsive to conventional therapies. In the EU, it is not widely approved; primarily marketed in the US under the brand Krystexxa (by Horizon Therapeutics). Regulatory dossiers demonstrate safety, efficacy, and manufacturing quality supported by clinical trial data. Both regions require detailed dossiers for initial approval and ongoing pharmacovigilance. For expert assistance with regulatory submissions, compliance, and registration, visit PharmaTradz. We facilitate efficient market access for pegloticase, ensuring adherence to European and US standards for safe, effective management of refractory gout, helping clients navigate complex regulatory landscapes seamlessly.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Colchicine tablest

Strength: 0.6 mg

Form: Tablet

Reference Brands: Colcrys(US)

View Details Get Enquiry
Febuxostat tablets

Strength: 40 mg, 80 mg

Form: Oral Tablets

Reference Brands: Uloric(EU & US)

View Details Get Enquiry
Allopurinol tablets

Strength: 100 mg, 300 mg

Form: Oral Tablets

Reference Brands: Aloprim(US & EU)

View Details Get Enquiry
Triamcinolone Injectable (IM, intra-articular)

Strength: 40 mg/mL, 80 mg/mL, 80 mg/2 mL

Form: Injectable (IM, intra-articular)

Reference Brands: Kenalog(US & EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.